View Clinical Trial (Medical Research Study)


Dose-finding and Safety Study of PVSRIPO Against Recurrent Glioblastoma

Signup
Browse Studies

City:   Durham
State:   North Carolina
Zip Code:   27710
Conditions:   Recurrent Supratentorial Glioblastoma Multiforme - GBM - Glioblastoma Multiforme
Purpose:   Purpose of the Study: To determine the maximally tolerated dose (MTD) and dose-limiting toxicity (DLT) of PVSRIPO when delivered intracerebrally by convection-enhanced delivery. To estimate progression-free and overall survival in resectable, recurrent supratentorial glioblastoma multiforme (GBM) patients. To evaluate immunologic, virologic and histopathologic parameters of the effect of virus infection on GBM tumors. Agent: PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus (PV) vaccine containing a heterologous internal ribosomal entry site (IRES) from human rhinovirus type 2 (HRV2). PVSRIPO recognizes Necl-5, an oncofetal cell adhesion molecule and tumor antigen widely expressed ectopically in malignancy, e.g. glioblastoma multiforme (GBM), as host cell receptor. PVSRIPO has been manufactured at NCI-Frederick, NCI, NIH. Catheter Implantation: PVS-RIPO will be delivered directly into the tumor. A stereotactic biopsy will be performed prior to virus administration for frozen section confirmation of viable tumor and further analysis. The biopsy needle will be placed with stereotactic guidance by an MRI-compatible, stereotactic head frame. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the OR at a site different from that used for the biopsy. A CT or MRI scan may be used to confirm catheter placement post-operatively. Agent infusion: The entire volume of the agent to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the OR at the time of the biopsy procedure. Drug infusion will occur in the NICU so that all other emergency facilities will be available. Patients will be infused through a Medfusion 3500 infusion pump pre-programmed to a delivery rate of 0.5 l/hr. The total amount of the inoculum delivered to the patient will be 3 ml. The virus injection procedure will be completed within 6.5 hrs. The catheter will be removed immediately following the delivery of PVSRIPO. Biopsy sampling and analyses: Biopsy material will be obtained from tumor tissue prior to virus administration. This tissue material will be subjected to routine histology to confirm tumor recurrence by the study neuropathologist, Dr. R. McLendon or his designate.
Study Summary:  
Criteria:   Inclusion Criteria: 1. Disease Status. Patients must have a resectable, recurrent supratentorial GBM based on imaging studies with measurable disease (≥ 1 cm or ≤ 5 cm of contrast-enhancing tumor). Prior histopathology consistent with a World Health Organization (WHO) Grade IV GBM confirmed by the study pathologist, Roger McLendon, or his designate. 2. Age. Due to the potential implications of the treatment on the developing CNS, all patients must be ≥ 18 years of age at the time of entry into the study. 3. Prior Therapy. Patients may be included in the study independent of the regimen of previous surgical, radiation, or chemotherapy treatments administered. However, the exclusions listed in #5 of the Exclusions below must be followed. 4. Performance Status. The patient must have a Karnofsky Performance Score (KPS) of ≥ 70% at the time of entry. 5. Laboratory Studies - Platelet count ≥ 100,000/ml - Prothrombin and Partial Thromboplastin Times ≤ 1.2 x normal - Positive serum anti-poliovirus titer - Creatinine ≤ 1.2 x normal - Total bilirubin, SGOT, SGPT, alkaline phosphatase ≤ 2.5 x normal - Neutrophil count ≥ 1000 - Hemoglobin ≥ 9 6. Poliovirus Immunization Booster. The subject must have received a boost immunization with monovalent inactivated (Salk) poliovirus vaccine type 1 at least 2 weeks prior to administration of the study agent. 7. Disease Confirmation. At the time of biopsy, prior to administration of virus, the presence of recurrent tumor must be confirmed by histopathological analysis of frozen sections. 8. Informed Consent. A signed informed consent form approved by the Duke University Institutional Review Board (IRB) will be required for patient enrollment into the study. Patients must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study. Exclusion Criteria: 1. Pregnancy. Because of the unknown risk of virus administration potentially affecting a developing fetus or growing infant, females who are pregnant or breast-feeding during the study period will be excluded. Adults of reproductive potential not employing an effective method of birth control will be excluded. Barrier contraceptives must be used throughout the trial in both sexes. 2. Disease Status. Because patients will receive drug intracerebrally, patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons, Allan Friedman or John Sampson, or their designate, will be excluded. 3. Medical Conditions. Because the potential toxicities from the agent being studied in this protocol may be similar to some known diseases or may be more dangerous in the context of certain known diseases, the following patients will be excluded to avoid confounding the study results: - Patients with an active infection requiring treatment or having an unexplained febrile illness (Tmax > 99.5 F). - Patients with known immunosuppressive disease or known human immunodeficiency virus infection. - Unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association Class 3 or 4) or lung (FEV1 < 50%) disease, uncontrolled diabetes mellitus. - Albumin allergy. Albumin is added to the agent as a stabilizer. Patients with a known allergy will be excluded. - Gadolinium allergy. Gadolinium is used as contrast for the MRI. 4. Previous Poliomyelitis. A history of neurological complications due to poliovirus infection would imply previous virus replication in the CNS. Based on animal studies, previous exposure to poliovirus administered intracerebrally can reduce subsequent virus replication in the CNS. 5. Prior Therapy. Patients who have not recovered from the toxic effects of prior chemotherapy and/or radiation therapy will be excluded. Guidelines for this recovery period are dependent upon the specific therapeutic agent being used. - Patients may not have received chemotherapy ≤ 4 weeks [except for nitrosourea (6 weeks) or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide (1 week)] prior to starting the study drug or patients have recovered from side effects of such therapy. - Patients may not have received immunotherapy ≤ 4 weeks prior to starting the study drug or patients have recovered from side effects of such therapy. - Patients may not have received investigational drugs ≤ 4 weeks prior to starting the study drug or must have recovered from side effects of such therapy. Patients must have completed all standard of care treatments including resection and concurrent chemo-radiation prior to participating in this trial. 6. Location and Extent of Tumor. Because of the potential toxicities from the agent, patients with neoplastic lesions in the brainstem, cerebellum or spinal cord, radiological evidence of multifocal disease, or leptomeningeal disease. Patients with evidence of diffuse subependymal disease or tumor in the brainstem, cerebellum, spinal cord, or CSF will be excluded. - Since the study agent is a local treatment, patients with radiological evidence of multifocal disease, tumors extending into or crossing the corpus callosum or leptomeningeal disease, will be excluded. - Patients with contrast-enhancing tumors of < 1 cm or > 5 cm diameter in any plane will be excluded. - Patients with tumor ≤ 1 cm in proximity to the ventricle. 7. Subjects must not have diagnosis of agammaglobulinemia. Patients with the following will be excluded: - IgG levels < 400 mg/dL [4 g/L] - Undetectable anti-tetanus toxoid IgG - Known history of agammaglobulinemia
NCT ID:   NCT01491893
Primary Contact:   Principal Investigator
Allan Friedman, MD
Duke University

Stevie Threatt
Phone: 919-684-3657
Email: stevie.threatt@duke.edu
Backup Contact:   Email: susan.boulton@duke.edu
Susan Boulton, RN
Phone: 919-668-0896
Location Contact:   Durham, North Carolina 27710
United States

Karen Carter
Phone: 919-668-2329
Email: karen.carter@duke.edu

Site Status: Recruiting

Data Source:   ClinicalTrials.gov
Date Processed:   July 27, 2014
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click I Am Interested In This Study

Full Name:
 
Email Address:
Confirm Email:
Daytime Phone (eg. 555-555-5555):
City:
State:
Zip Code:
Best Time to Call:
Questions/Comments:
  • NEARBY STUDIES

    (updated 47 minutes ago)
Within 25 Miles

Smoking - Durham NC

COPD (Chronic Obstructive Pulmonary Disease) - Raleigh NC

Asthma - Raleigh NC

Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation - Durham NC

Melanoma Vaccine - Raleigh NC

Lower Back Pain Radiating to the Legs - Raleigh NC

Actinic Keratosis - Raleigh NC

Rheumatoid Arthritis - Raleigh NC

Nocturia - Raleigh NC

Osteoarthritis of the Knee - Raleigh NC

Smoking Cessation - Durham NC

Mild Alzheimer's Disease - Raleigh NC

Alzheimer's Disease - Raleigh NC

Plaque Psoriasis - Raleigh NC

Adolescent Major Depression (Ages 12-17) - Durham NC

Amenorrhea - Raleigh NC

Chronic Constipation - Raleigh NC

Acne - Raleigh NC

Gastroparesis - Raleigh NC

Iron Deficiency Anemia & Inflammatory Bowel Syndrome - Raleigh NC

Knee Pain - Raleigh NC

Asthma - Durham NC

H. Pylori - Raleigh NC

Moderate Psoriasis - Raleigh NC

Type 2 Diabetes with High Blood Pressure - Raleigh NC

Obesity and Cardiovascular Disease - Raleigh NC

Gastroparesis - Raleigh NC

Heartburn - Raleigh NC

Hot Flashes - Raleigh NC

Healthy Volunteers - Raleigh NC

ADHD - Raleigh NC

Gout - Raleigh NC

Parkinson's Disease - Raleigh NC

Osteoarthritis Hip Pain - Raleigh NC

Ulcerative Colitis - Raleigh NC

Crohn's Disease - Raleigh NC

Acne Gel - Raleigh NC

Gastroparesis - Raleigh NC

Frozen Shoulder - Raleigh NC

Plaque Psoriasis (Moderate to Severe) - Raleigh NC

Mild Asthma - Raleigh NC

Facial Redness Due to Rosacea - Raleigh NC

Obesity and Heart Disease Risk - Raleigh NC

Type 1 Diabetes - Raleigh NC

Uterine Fibroids - Raleigh NC

Diabetic Gastroparesis - Raleigh NC

High Cholesterol - Cary NC

Asthma in Children (Ages 5-11) - Raleigh NC

COPD (Emphysema and Chronic Bronchitis) - Raleigh NC

Within 50 Miles

Lupus - Danville VA

Diabetic Gastroparesis - Greensboro NC

High Cholesterol - Burlington NC

High Cholesterol - Greensboro NC

Migraines - Greensboro NC

Within 100 Miles

Chronic Itch - High Point NC

Type 2 Diabetes - High Point NC

Diabetic Foot Sores - Greenville NC

Diabetic Foot Sores - Salisbury NC

Asthma - Winston Salem NC

Healthy Volunteers - High Point NC

Multiple Sclerosis - Winston Salem NC

Chronic Obstructive Pulmonary Disease (COPD, Emphysema) - High Point NC

Endometriosis - High Point NC

Endometriosis - Winston Salem NC

Chronic Constipation - High Point NC

Overweight with Known Heart Problems - High Point NC

Benign Prostatic Hyperplasia - High Point NC

Benign Prostatic Hyperplasia - Winston Salem NC

Parkinson's Disease - Winston Salem NC

Diabetic Gastroparesis - Winston Salem NC

Diabetic Gastroparesis - Fayetteville NC

High Cholesterol - Winston Salem NC

High Cholesterol - Salisbury NC

Chronic Obstructive Pulmonary Disease (COPD) - Winston Salem NC

Chronic Obstructive Pulmonary Disease (COPD) - Salisbury NC